Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/25/16  and contains information from public web pages and contributions from the ZoomInfo community.

David Verbraska

Wrong David Verbraska?

Vice President, Worldwide Policy ...

Phone: (212) ***-****  
Pfizer Inc
235 E 42Nd St
New York , New York 10017
United States

Company Description: Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health and well-being at...   more

Employment History

26 Total References
Web References
Cardinal Health Amends Syncor Deal, 4 Dec 2002 [cached]
Cardinal Health spokesman David Verbraska said the new exchange ratio reflects the discovery of the improper payments.
"The important point for us is that we feel satisfied that we can move forward with the acquisition in accordance with our high standards," he said.
The changes were made after Syncor said it was investigating questionable payments by the subsidiary, Syncor Taiwan Inc., to customers in Taiwan and at least six other countries.The subsidiary made improper payments to employees of state-owned health care facilities in Taiwan.
Cardinal Health and Syncor, based in Woodland Hills, Calif., near Los Angeles, say they expect the deal to close by January.
Nuclear pharmacy services, also called radiopharmacy, involve the use of radioactive compounds that are ingested or injected in organs or tissues.
Pharma Exec Blog » Op-Ed, 2 July 2014 [cached]
Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer, noted the FDA stood at an “inflection pointâ€� in transitioning from simply engaging with patient groups to demonstrating how patient needs and outcomes rest at the center of drug review, based on clear metrics understood by all. As FDA tries to work out the finer points of the law, Pfizer relies on a simple metric in advancing the patient perspective. “Our goal is to innovate in bringing new therapies to patients that significantly improve their lives. We leave it to each patient to define what ‘significantly’ means, based on their own unique experience â€" it could be in helping to establish the right endpoints in a trial or shaping a post-marketing approval study that tracks safety and side-effect profiles.â€�
Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer.
Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer.
At the FDA, however, engagement with the patient is still more of an experiment, with highly variable expectations coming from each side â€" and industry is often caught in the middle. “Patient groups will say they desire more contact, or that things are not moving fast enough at the FDA for them. We then have to ask what level of involvement do you want, and to what end?â€� No one yet has a definitive response to these questions.â€� Instead of having to constantly reframe the discussion, Verbraska says what the industry needs is a clearly articulated pathway to collaborate with patient groups in informing and shaping decisions on market authorizations from the FDA.
The panel â€" which included, in addition to Verbraska, Andrew Emmett, Managing Director for Scientific and Regulatory Affairs at BIO; Marc Boutin, Chief Operating Officer of the National Health Council, and Kimberly McCleary, Director of Strategic Initiatives at Faster Cures â€" suggested a number of improvements to the “Voice of the Patientâ€� process, as follows:
Professional Development Seminars Focused on Corporate Communications Issues at the 2004 PRSA International Conference, 8 Oct 2004 [cached]
David Verbraska, director of communications, Pfizer, Inc., New York
PR Summit - The Organization for Public Relations Leaders, 1 June 2013 [cached]
Pfizer, David Verbraska, VP of Worldwide Policy & Public Affair
Upcoming Events |  Expert Briefings, 15 June 2011 [cached]
Representing the other side of the coin, David Verbraska, Pfizer's vp, regulatory policy, said, "Should FDA choose to mandate public disclosure of investigator financial information, Pfizer recommends that the agency not require listing of specific payments or dollar amounts.
Other People with the name "Verbraska":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.